NCT02459119View on ClinicalTrials.gov

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

April 30, 2020

Conditions
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Interventions
DRUG

Regorafenib

Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.

Trial Locations (3)

35294

University of Alabama at Birmingham, Birmingham

44195

Cleveland Clinic, Cleveland

48201-2013

Wayne State University, Detroit

All Listed Sponsors
collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT02459119 - Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) | Biotech Hunter | Biotech Hunter